Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma

International Journal of Oncology

Volumn 47, Issue 3, 2015, Pages 867-874

  Tsutsui, Mai ^a   Kawakubo, Hirofumi ^a   Hayashida, Testsu ^a   Fukuda, Kazumasa ^a   Nakamura, Rieko ^a   Takahashi, Tsunehiro ^a   Wada, Norihito ^a   Saikawa, Yoshiro ^a   Omori, Tai ^a   Takeuchi, Hiroya ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cisplatin; Drug resistance; Esophageal cancer; Gene; Transposon

Indexed keywords

CISPLATIN; GENOMIC DNA; JANUS KINASE 2; PUROMYCIN; ANTINEOPLASTIC AGENT; TRANSPOSON;

ARTICLE; BACTERIUM COLONY; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE IDENTIFICATION; GENE INSERTION; GENE LIBRARY; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC RESISTANCE; GENETIC SCREENING; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; MOLECULAR CLONING; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; TRANSPOSON; CELL SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; DRUG RESISTANCE; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; PROCEDURES; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CLONING, MOLECULAR; DNA MUTATIONAL ANALYSIS; DNA TRANSPOSABLE ELEMENTS; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS;

EID: 84938054150     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3085     Document Type: Article

References (23)

1. Z acherl J: The current evidence in support of multimodal treatment of locally advanced, potentially resectable esophageal cancer. Dig Dis 32: 171-175, 2014.
2. M insky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 20: 1167-1174, 2002.
3. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, et al; Japan Clinical Oncology Group: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study -JCOG9204. J Clin Oncol 21: 4592-4596, 2003.
4. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19: 68-74, 2012.
5. Zhu L, Du H, Shi M, Chen Z and Hang J: ATG deficiency promote apoptotic death induced by Cisplatin in human esophageal squamous cell carcinoma cells. Bull Cancer 100: 15-21, 2013.
6. Sato Y, Motoyama S, Nanjo H, Ito S, Yoshino K, Sasaki T, Kuribayashi K, Nagaki Y, Imai K, Saito H, et al: REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy. Ann Surg Oncol 20: 3044-3051, 2013.
7. Guo W, Zhao YP, Jiang YG, Wang RW, Hong L and Fan DM: Upregulation of ZNRD1 enhances cisplatin resistance in human esophageal cancer cells by regulation of ERCC1 and Bcl-2. Tumour Biol 29: 188-194, 2008.
8. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 5: 358: 2482-2494, 2008.
9. Nooter K, Kok T, Bosman FT, van Wingerden KE and Stoter G: Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to preoperative chemotherapy. Eur J Cancer 34: 81-86, 1998.
10. Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ, Zhang X, Li YF and Fu JH: Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep 22: 65-71, 2009.
11. Sakai NS, Samia-Aly E, Barbera M and Fitzgerald RC: A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol 23 (6 Pt B): 512-521, 2013.
12. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K, et al: Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 61: 6474-6479, 2001.
13. Shimoji T, Miki Y and Nagasaki K: Gene expression profiling for prediction of response to chemotherapy. Gan To Kagaku Ryoho 33: 1-5, 2006 (In Japanese).
14. Chen LI, Stuart L, Ohsumi TK, Burgess S, Varshney GK, Dastur A, Borowsky M, Benes C, Lacy-Hulbert A and Schmidt EV: Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics. BMC Cancer 13: 93, 2013.
15. Li X, Burnight ER, Cooney AL, Malani N, Brady T, Sander JD, Staber J, Wheelan SJ, Joung JK, McCray PB Jr, et al: PiggyBac transposase tools for genome engineering. Proc Natl Acad Sci USA 110: E2279-E2287, 2013.
16. Hay RJ, Park J-G and Gazdar A (eds): Atlas of Human Tumor Cell Lines. Academic Press, pp269-282, 1994.
17. Nishihira T, Hashimoto Y, Katayama M, Mori S and Kuroki T: Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 119: 441-449, 1993.
18. Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
19. Ihle JN and Gilliland DG: Jak2: Normal function and role in hematopoietic disorders. Curr Opin Genet Dev 17: 8-14, 2007.
20. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397, 2005.
21. Sumi K, Tago K, Kasahara T and Funakoshi-Tago M: Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells. Febs Lett 585: 1884-1890, 2011.
22. Wang LS, Chow KC and Wu CW: Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer 80: 1617-1622, 1999.
23. Suchi K, Fujiwara H, Okamura S, Okamura H, Umehara S, Todo M, Furutani A, Yoneda M, Shiozaki A, Kubota T, et al: Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res 31: 67-75, 2011.